February 19, 2025 Advancing Neonatal Drug Development Through Collaboration At C-Path’s INC, we believe that meaningful progress in neonatal drug development...
February 18, 2025 C-Path’s CPA-1 Consortium Welcomes Newest Members Kamada, Sanofi Critical Path for Alpha-1 (CPA-1) consortium today announced the addition of biopharmaceutical companies, Kamada...
February 13, 2025 Breaking the silence: challenges and opportunities in pediatric drug development Pediatric drug development faces significant challenges, including underfunding, ethical concerns, and complex regulatory...
February 3, 2025 Living with Huntington’s Disease: A Conversation on Advocacy, Mental Health, and Self-Care I recently had the privilege of sitting down with Lauren Holder, Producer and Host of the Help 4 HD podcast, who is also a...
February 1, 2025 Increased discoverability of rare disease datasets through knowledge graph integration Healthcare datasets can be used for many different purposes in the pursuit of...
February 1, 2025 Accelerating Parkinson’s Disease Drug Development with Federated Learning Approaches Parkinson’s Disease is a progressive neurodegenerative disorder afflicting almost 12 million people...
February 1, 2025 Understanding what aspects of Parkinson’s disease matter most to patients and families Understanding what matters to people with Parkinson’s and their family is essential to derive relevant clinical outcome measures
January 31, 2025 Integrating Complex In Vitro Models Into the Regulatory Pipeline C-Path has developed a framework to support FDA qualification of CIVMs for use in regulatory submissions...
January 28, 2025 TRxA Funding Opportunities 2025 On January 28, C-Path’s Translational Therapeutics Accelerator (TRxA)...
January 28, 2025-January 29, 2025 2025 CRDSA Summit Recordings Available Featuring a keynote address by C-Path CEO Klaus Romero, the first day of...